Corresponding Author: Siri Lillegraven, MD, MPH, PhD, Division of Rheumatology and Research, Diakonhjemmet Hospital, PO Box 23 Vinderen, N-0319 Oslo, Norway (email@example.com).
Accepted for Publication: March 11, 2021.
Author Contributions: Drs Lillegraven and Sexton had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Lillegraven, Paulshus Sundlisæter, and Aga share first authorship.
Concept and design: Lillegraven, Aga, Olsen, Lexberg, Uhlig, Solomon, van der Heijde, Kvien, Haavardsholm.
Acquisition, analysis, or interpretation of data: Lillegraven, Paulshus Sundlisæter, Aga, Sexton, Olsen, Fremstad, Spada, Madland, Høili, Bakland, I. J. W. Hansen, I. M. Hansen, Haukeland, Ljoså, Moholt, Uhlig, Kvien, Haavardsholm.
Drafting of the manuscript: Lillegraven, Paulshus Sundlisæter, Aga, Sexton, Lexberg, Uhlig.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Lillegraven, Aga, Sexton, Olsen, Kvien, Haavardsholm.
Obtained funding: Lillegraven, Høili, Haavardsholm.
Administrative, technical, or material support: Lillegraven, Paulshus Sundlisæter, Aga, Sexton, Spada, Madland, Høili, Bakland, Lexberg, I. J. W. Hansen, I. M. Hansen, Haukeland, Ljoså, Moholt, Kvien, Haavardsholm.
Supervision: Lillegraven, Aga, Lexberg, Uhlig, Kvien, Haavardsholm.
Other—delivery of patient data from our center: Fremstad.
Conflict of Interest Disclosures: Dr Lillegraven reported receiving grants from the Research Council of Norway and South-Eastern Norway Regional Health Authority during the conduct of the study. Dr Paulshus Sundlisæter reported receiving grants from the Research Council of Norway and South-Eastern Norway Regional Health Authority during the conduct of the study. Dr Aga reported receiving personal fees from AbbVie, Eli Lilly, Novartis, and Pfizer outside the submitted work. Dr Olsen reported his institution receiving reimbursement for data management services from Diakonhjemmet Hospital during the conduct of the study. Dr Madland reported receiving personal fees from Novartis for lectures outside the submitted work. Dr Bakland reported receiving personal fees from UCB, AbbVie, and Novartis outside the submitted work. Dr Haukeland reported receiving personal fees from Novartis outside the submitted work. Mrs Moholt reported receiving grants from the Research Council of Norway and South-Eastern Norway Regional Health Authority during the conduct of the study. Dr Uhlig reported receiving personal fees from Eli Lilly, Novartis, and Pfizer outside the submitted work. Dr Solomon reported receiving nonfinancial support from Amgen and grants from AbbVie, Corrona, Janssen, and Genentech during the conduct of the study. Dr van der Heijde reported receiving personal fees from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi Sankyo, Eisai, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma outside the submitted work and serving as director of Imaging Rheumatology BV. Dr Kvien reported receiving grants from AbbVie, Merck Sharp & Dohme, Novartis, Pfizer, UCB, and Bristol Myers Squibb and personal fees from AbbVie, Biogen, Celltrion, Egis, Eli Lilly, Merck Sharp & Dohme, Mylan, Hikma, Novartis, Oktal, Orion Pharma, Pfizer, Roche, Sandoz, Sanofi, UCB, and Gilead outside the submitted work. Dr Haavardsholm reported receiving grants from the Research Council of Norway and South-Eastern Norway Regional Health Authority during the conduct of the study and personal fees from Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Eli Lilly, and UCB outside the submitted work. No other disclosures were reported.
Funding/Support: The study was funded by the Research Council of Norway and South-Eastern Norway Regional Health Authority.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank the patients who have participated in the study, and we are grateful for the time and effort they have invested in the project. We thank the investigators, study nurses, and medical staff at the study centers for the invaluable contribution to the study. We are grateful to Camilla Fongen (PT, MSc, Diakonhjemmet Hospital, who received compensation for her role as project coordinator) for the contribution to the organization of the study and the data collection; the Department for Immunology and Transfusion Medicine at Oslo University Hospital for analyses of serological markers; our patient partners Ola-Jacob Sønsthagen and Eli Ormerod (BSc) (they did not receive compensation); and the funding sources.
B , Rincheval
N , Benessiano
et al. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol
. 2013;40(10):1650-1657. doi:10.3899/jrheum.121515PubMedGoogle ScholarCrossref
NB , van der Kooij
SM , Güler-Yüksel
et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis
. 2011;70(2):315-319. doi:10.1136/ard.2010.136556PubMedGoogle ScholarCrossref
JS , Emery
P , Fleischmann
et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet
. 2014;383(9914):321-332. doi:10.1016/S0140-6736(13)61751-1PubMedGoogle ScholarCrossref
N , van der Maas
A , Minten
et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ
. 2015;350:h1389. doi:10.1136/bmj.h1389PubMedGoogle ScholarCrossref
D , Neogi
T , Silman
et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis
. 2010;69(9):1580-1588. doi:10.1136/ard.2010.138461PubMedGoogle ScholarCrossref
van der Heijde
DM , van ’t Hof
MA , van Riel
et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis
. 1990;49(11):916-920. doi:10.1136/ard.49.11.916PubMedGoogle ScholarCrossref
ML , van Gestel
AM , van T Hof
MA , van Rijswijk
MH , van de Putte
LB , van Riel
PL . Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol
. 1996;35(11):1101-1105. doi:10.1093/rheumatology/35.11.1101PubMedGoogle ScholarCrossref
DT , Smolen
JS , Wells
et al; American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum
. 2011;63(3):573-586. doi:10.1002/art.30129PubMedGoogle ScholarCrossref
ML , van ’t Hof
MA , Kuper
HH , van Leeuwen
MA , van de Putte
LB , van Riel
PL . Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum
. 1995;38(1):44-48. doi:10.1002/art.1780380107PubMedGoogle ScholarCrossref
D , Smolen
J . The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol
. 2005;23(5)(suppl 39):S100-S108.PubMedGoogle Scholar
DM , Boyle
JA , McInnes
et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med
. 1968;37(147):393-406.PubMedGoogle Scholar
L , Paternotte
S , Aanerud
et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis
. 2011;70(6):935-942. doi:10.1136/ard.2010.142901PubMedGoogle ScholarCrossref
HB , Bolton-King
P , Bakkeheim
et al. Examination of intra and interrater reliability with a new ultrasonographic reference atlas for scoring of synovitis in patients with rheumatoid arthritis. Ann Rheum Dis
. 2011;70(11):1995-1998. doi:10.1136/ard.2011.152926PubMedGoogle ScholarCrossref
van der Heijde
D . How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol
. 1999;26(3):743-745.PubMedGoogle Scholar
AM , Prevoo
ML , van ’t Hof
MA , van Rijswijk
MH , van de Putte
LB , van Riel
PL . Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum
. 1996;39(1):34-40. doi:10.1002/art.1780390105PubMedGoogle ScholarCrossref
US Department of Heath and Human Services; Food and Drug Administration. Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA). US Dept of Health and Human Services; 1999.
US Department of Health and Human Services; Food and Drug Administration. Non-inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry. US Dept of Health and Human Services; 2016.
TK , Heiberg
MS , Lie
et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol
. 2005;23(5)(suppl 39):S188-S194.PubMedGoogle Scholar
E , de Jong
PHP , Kuijper
et al. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis
. 2019;78(6):746-753. doi:10.1136/annrheumdis-2018-214970PubMedGoogle ScholarCrossref
J , Englbrecht
M , Hueber
et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis
. 2016;75(1):45-51. doi:10.1136/annrheumdis-2014-206439PubMedGoogle ScholarCrossref
R , van der Heijde
D , van der Linden
S , Boers
M . Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis
. 2006;65(5):637-641. doi:10.1136/ard.2005.039859PubMedGoogle ScholarCrossref